Survodutide vs BI 456906: Key Differences Explained

Survodutide and BI 456906 aren't two different drugs competing for the same indication. They're the same molecule at different points in clinical development. Boehringer Ingelheim initially assigned the molecule the research designation 'BI 456906' during Phase I and early Phase II trials. As the compound advanced into late-stage trials and approached potential FDA submission, the company rebranded it 'survodutide'. A name that follows International Nonproprietary Name (INN) conventions and signals a transition from research compound to investigational new drug with commercial potential. This naming pattern is standard pharmaceutical practice: research codes (BI, BMS, AZ) get replaced by INN-approved generic names as molecules progress through clinical validation.

Our team tracks emerging peptide therapeutics across clinical pipelines, and we've watched survodutide progress from preclinical studies through Phase III trials. The confusion around naming is common. Researchers citing early-phase data still reference BI 456906, while recent publications use survodutide, creating the false impression that two separate compounds exist. They don't.

What's the difference between survodutide and BI 456906?

Survodutide and BI 456906 are identical. The same dual GLP-1/glucagon receptor agonist developed by Boehringer Ingelheim. BI 456906 was the internal research code used during early clinical trials, while survodutide is the International Nonproprietary Name (INN) assigned as the compound advanced toward regulatory approval. The molecular structure, mechanism of action, and pharmacokinetic profile remain unchanged. Only the nomenclature evolved to align with pharmaceutical naming conventions for drugs approaching market readiness.

Here's what often gets missed when people encounter both names: the transition from research code to INN isn't arbitrary. Pharmaceutical companies apply for INN designation from the World Health Organization once clinical efficacy data justifies potential regulatory submission. The shift signals confidence in the molecule's commercial viability. This piece covers exactly what survodutide is, how its dual-agonist mechanism differs from single-target GLP-1 drugs like semaglutide, what clinical trial data exists under both names, and what researchers should understand when sourcing or citing the compound.

Molecular Identity and Mechanism: Same Compound, Different Labels

Survodutide (BI 456906) is a dual GLP-1/glucagon receptor agonist. Meaning it activates both incretin receptors simultaneously rather than targeting GLP-1 alone. This distinguishes it mechanistically from semaglutide (Wegovy, Ozempic) and liraglutide (Saxenda, Victoza), which act exclusively on GLP-1 receptors. The glucagon receptor activation component increases energy expenditure and hepatic fat oxidation. Pathways that GLP-1-only agonists don't directly engage. In Phase II trials published in The Lancet Diabetes & Endocrinology (2021), survodutide demonstrated dose-dependent weight reduction of up to 14.7% at 48 weeks in patients with type 2 diabetes, alongside significant reductions in liver fat content measured by MRI-PDFF (proton density fat fraction).

The dual-agonist design targets two complementary pathways: GLP-1 receptor activation slows gastric emptying and reduces appetite through hypothalamic satiety signaling, while glucagon receptor activation stimulates lipolysis and increases resting energy expenditure by 5–8% in metabolic studies. This combination addresses both caloric intake and caloric expenditure. A pharmacological approach distinct from incretin-only therapies. Research teams studying metabolic dysfunction-associated steatohepatitis (MASH) have shown particular interest in survodutide's hepatic effects, as glucagon signaling directly promotes mitochondrial beta-oxidation in hepatocytes.

Clinical Trial Nomenclature: Tracking the Same Molecule Across Publications

Early-phase trials (2018–2020) published under the designation BI 456906 established safety, tolerability, and preliminary efficacy signals. ClinicalTrials.gov entries from this period list the compound as BI 456906, as do peer-reviewed publications in Diabetes, Obesity and Metabolism and The Journal of Clinical Endocrinology & Metabolism. Once Boehringer Ingelheim received INN approval in 2020, subsequent Phase IIb and Phase III trials adopted the name survodutide. This creates citation challenges. Researchers cross-referencing early pharmacokinetic data with recent efficacy studies encounter two names for the same molecule.

The Phase III SYNCHRONIZE program, initiated in 2023, exclusively uses survodutide nomenclature across four trials: SYNCHRONIZE-1 (obesity without diabetes), SYNCHRONIZE-2 (obesity with type 2 diabetes), SYNCHRONIZE-NAFLD (metabolic dysfunction-associated steatotic liver disease), and SYNCHRONIZE-HFpEF (heart failure with preserved ejection fraction). These trials evaluate the compound at doses ranging from 2.4mg to 9.6mg administered subcutaneously once weekly. For researchers sourcing real peptides for metabolic studies, understanding that BI 456906 and survodutide reference the same molecular entity prevents redundant literature reviews and ensures comprehensive data capture.

Survodutide vs BI 456906: Full Clinical Comparison

Key Takeaways

• Survodutide and BI 456906 are the same dual GLP-1/glucagon receptor agonist. The naming difference reflects clinical trial phase progression, not molecular variation.
• BI 456906 was the internal research code used during Phase I and early Phase II studies conducted between 2018 and 2020.
• Survodutide became the official International Nonproprietary Name (INN) in 2020, replacing BI 456906 in all Phase IIb and Phase III trial documentation.
• The dual-agonist mechanism activates both GLP-1 receptors (appetite suppression, gastric emptying) and glucagon receptors (energy expenditure, hepatic fat oxidation), differentiating it from GLP-1-only drugs like semaglutide.
• Phase III SYNCHRONIZE trials (2023–2026) exclusively use survodutide nomenclature and are evaluating the compound for obesity, type 2 diabetes, MASH, and heart failure with preserved ejection fraction.
• Researchers citing clinical data should use BI 456906 when referencing pre-2021 publications and survodutide for all subsequent studies to maintain bibliographic accuracy.

What If: Survodutide and BI 456906 Scenarios

What If I Find Research Papers Using Both Names — Are They Studying Different Compounds?

No. They're studying the same molecule at different trial phases. Cross-reference publication dates: papers before mid-2020 use BI 456906, while those after 2021 use survodutide. Both names describe the dual GLP-1/glucagon agonist developed by Boehringer Ingelheim. The molecular structure, amino acid sequence, and pharmacological profile are identical. When conducting systematic reviews or meta-analyses, include both search terms ('BI 456906' AND 'survodutide') to capture the full body of evidence. Otherwise you'll miss early-phase safety and pharmacokinetic data published under the research code.

What If I'm Sourcing Peptides for Research — Which Name Should I Use When Ordering?

Use survodutide when communicating with suppliers, as it's the WHO-approved INN and the name most synthesis labs recognize for 2026 orders. Research-grade peptide suppliers like Real Peptides synthesize compounds based on INN designations and molecular structure specifications, not internal pharmaceutical codes. If ordering from a supplier unfamiliar with survodutide, provide the dual GLP-1/glucagon agonist mechanism and reference CAS Registry Number 2381089-83-2 (if assigned) to eliminate ambiguity. BI 456906 may not appear in current peptide catalogs, as it was never the compound's official public-facing name.

What If Clinical Trial Results Are Published Under BI 456906 — Can I Cite Them in 2026 Research?

Yes, but clarify the nomenclature in your citation. When referencing early-phase trials, write: 'BI 456906 (now designated survodutide) demonstrated…' to prevent reader confusion. This is particularly important in grant applications, where reviewers may not recognize BI 456906 as survodutide without explicit notation. ClinicalTrials.gov entries from 2018–2020 retain the BI 456906 identifier, so direct hyperlinks to trial records will display the research code even though the compound is now commercially referred to by its INN.

The Evidence-Based Truth About Pharmaceutical Nomenclature

Here's the honest answer: the pharmaceutical industry's transition from research codes to INNs confuses researchers, clinicians, and patients. But it's not arbitrary. The shift signals that a molecule has progressed from exploratory research to serious regulatory consideration. BI 456906 was an internal Boehringer Ingelheim designation used when the compound's commercial future was uncertain. Once Phase IIa data showed statistically significant weight reduction and liver fat improvement, the company applied for INN status. Survodutide was born. This isn't unique to this compound: semaglutide was once NN9535, tirzepatide was LY3298176, and orforglipron (another GLP-1 agonist our team tracks) was LY3502970 before receiving its INN.

The bottom line: if you encounter both names in literature, clinical trial databases, or supplier catalogs, you're looking at the same dual GLP-1/glucagon agonist at different developmental stages. The molecule didn't change. The branding strategy did. For researchers interested in metabolic peptides beyond survodutide, our FAT Loss Stack and FAT Loss Metabolic Health Bundle feature research-grade compounds synthesized with exact amino-acid sequencing and verified purity for lab reliability.

The nomenclature distinction matters most when conducting systematic reviews, meta-analyses, or preclinical studies where comprehensive literature coverage is critical. Search both terms, note the publication date, and recognize that early safety and PK data under BI 456906 remain valid and citable. The molecular pharmacology hasn't changed. The regulatory positioning has. If you're tracking this compound through Phase III trials and potential FDA submission, survodutide is now the only name that will appear in regulatory filings, product labeling (if approved), and post-market surveillance databases.

For labs conducting comparative studies of incretin-based therapies, understanding that survodutide's dual-agonist design differs fundamentally from GLP-1-only drugs matters more than the naming convention. The glucagon receptor component increases energy expenditure by 150–250 kcal/day in metabolic chamber studies. A pathway semaglutide doesn't engage. That mechanistic distinction, not the nomenclature evolution, defines survodutide's therapeutic niche and research value.